~~<i id='CFDA187BAC'><strike id='CFDA187BAC'><tt id='CFDA187BAC'><pre id='CFDA187BAC'></pre></tt></strike></i>~~

Home» comprehensive» knowledge

knowledge

author：Wikipedia 2025-09-28 11:37:22 Page View：17227

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BD to buy Edwards patient monitoring unit for $4.2 billion
Next article： Continuity nursing helped my family in our darkest PICU moments

explore

Activists slam private health insurers over coverage restrictions

ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

FDA early review: GLP

SarahSilbiger/GettyImagesApreliminaryevaluationbytheFoodandDrugAdministrationdidnotfindevidencethatG

Trump demands the U.S. pay no more for drugs than other countries … again

EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest

ASCO Daily Recap: CAR

AdobeYou’rereadingthewebeditionofASCOin30Seconds,STAT’sguidetotheAmericanSocietyofClinicalOncologyan